226. 間質性膀胱炎（ハンナ型） Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 145 / 薬物数 : 156 - (DrugBank : 51) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 146
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
AGN 203818
Allergan
2006 Phase 2 NCT00380783 United States;
AQX-1125
Aquinox Pharmaceuticals (Canada) Inc.
2017 Phase 3 EUCTR2016-000906-12-NL Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000906-12-ES Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000906-12-BE Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States;
2016 Phase 3 NCT02858453 Belgium;Canada;Czech Republic;Czechia;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000906-12-LV Belgium;Canada;Czech Republic;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000906-12-HU Belgium;Canada;Czech Republic;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000906-12-GB Belgium;Canada;Czech Republic;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000906-12-DK Belgium;Canada;Czech Republic;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000906-12-CZ Belgium;Canada;Czech Republic;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States;
2013 Phase 2 NCT01882543 Canada;United States;
ASP3652
Astellas Pharma Europe B.V.
2013 - EUCTR2011-004555-39-LT Belgium;Czech Republic;Denmark;France;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 Phase 2 NCT01613586 Belgium;Czech Republic;Czechia;Denmark;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 Phase 2 EUCTR2011-004555-39-BE Belgium;Czech Republic;Denmark;France;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 - EUCTR2011-004555-39-PT Belgium;Czech Republic;Denmark;France;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 - EUCTR2011-004555-39-PL Belgium;Czech Republic;Denmark;France;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 - EUCTR2011-004555-39-NL Belgium;Czech Republic;Denmark;France;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 - EUCTR2011-004555-39-LV Belgium;Czech Republic;Denmark;France;Germany;Italy;Latvia;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 - EUCTR2011-004555-39-ES Belgium;Czech Republic;Denmark;France;Germany;Latvia;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 - EUCTR2011-004555-39-DK Belgium;Czech Republic;Denmark;France;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 - EUCTR2011-004555-39-DE Belgium;Czech Republic;Denmark;France;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 - EUCTR2011-004555-39-CZ Belgium;Czech Republic;Denmark;France;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
ASP6294
Astellas Pharma Europe B.V.
2017 Phase 2 NCT03282318 Belgium;Czechia;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004138-12-PL Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004138-12-NL Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004138-12-LV Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004138-12-HU Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004138-12-GB Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004138-12-ES Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004138-12-DE Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004138-12-CZ Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004138-12-BE Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
Adalimumab
ICStudy, LLC
2011 Phase 3 NCT01295814 United States;
Alkalinized Lidocaine-Heparin
Urigen
2006 Phase 2 NCT00256542 United States;
AlloRx
The Foundation for Orthopaedics and Regenerative Medicine
2021 Phase 1 NCT05147779 Antigua and Barbuda;
Amitriptyline
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2005 Phase 3 NCT00124306 Canada;United States;
BOTOX 100U in normal saline
Buddhist Tzu Chi General Hospital
2021 Phase 2 NCT05275647 Taiwan;
BOTOX 200U in normal saline
Buddhist Tzu Chi General Hospital
2014 Phase 2 NCT02247557 Taiwan;
Bladder Instillations
William Beaumont Hospitals
2017 Phase 2 NCT02870738 United States;
Bladder instillation WITH triamcinolone acetonide
Olivia Cardenas-Trowers, M.D.
2019 Phase 3 NCT03463915 United States;
Bladder instillation WITHOUT triamcinolone acetonide
Olivia Cardenas-Trowers, M.D.
2019 Phase 3 NCT03463915 United States;
Bladder instillation with heparin/ lidocaine
Scripps Health
2012 Phase 2 NCT01048177 United States;
Botox
University of Washington
2004 Phase 4 NCT00194610 United States;
research office urology VUmc
2008 - EUCTR2007-005164-27-NL Netherlands;
Botulinum toxin A
Buddhist Tzu Chi General Hospital
2012 Phase 2 NCT01969773 Taiwan;
Buckwheat
Center for Pharma-Food Research, Graduate School of Pharmaceutical Sciences, University of Shizuoka
2017 - JPRN-UMIN000029113 Japan;
Bupivacaine
Case Western Reserve University
2009 - NCT01616992 United States;
Bupivacaine, triamcinolone, and heparin (BTH)
NorthShore University HealthSystem
2011 Phase 4 NCT05223244 -
Cannabidiol vaginal suppository
University of New Mexico
2021 Phase 1 NCT04349930 United States;
Capsaicin
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1995 Phase 1/Phase 2 NCT00004316 -
Certolizumab pegol
ICStudy, LLC
2015 Phase 3 NCT02497976 United States;
Ciklosporin
Ingrid Ehrén
2005 - EUCTR2005-000890-23-SE Sweden;
Combination Product: Hyperbaric Oxygen Therapy-
University of California, San Diego
2017 Early Phase 1 NCT03143920 United States;
Cyclosporine
The Cleveland Clinic
2013 Phase 2 NCT01990898 United States;
DMSO
Assaf-Harofeh Medical Center
2010 - NCT01069263 Israel;
Deparment of Urology, Medical Science, University of Fukui
2005 - JPRN-UMIN000003172 Japan;
Department of Urology, Hamamatsu University School of Medicine
2004 - JPRN-UMIN000027494 Japan;
Urology, Hokkaido University Graduate School of Medicine
2014 - JPRN-UMIN000014860 Japan;
DMSO cocktail
Assaf-Harofeh Medical Center
2009 - NCT01074567 Israel;
Desert Harvest Aloe Vera Capsules
Wake Forest University Health Sciences
2022 Early Phase 1 NCT04734106 United States;
Dexmedetomidine
University of Rochester
2010 Phase 4 NCT01195116 United States;
Dextrose
National Defense Medical Center, Taiwan
2019 - NCT04821882 Taiwan;
Dimethyl sulfoxide
Capital District Health Authority, Canada
2006 Phase 2 NCT00317070 Canada;
IBSA
2011 - EUCTR2010-021556-25-IT Italy;
Kyorin Pharmaceutical Co.,LTD
2017 Phase 3 JPRN-JapicCTI-173566 Japan;
Dimethyl sulfoxide (DMSO)
NorthShore University HealthSystem
2011 Phase 4 NCT05223244 -
ERB-041
Wyeth is now a wholly owned subsidiary of Pfizer
2006 - NCT00275379 Austria;Germany;United States;
Flavoxate
Torimoto Kazumasa
2021 Phase 2 JPRN-jRCTs051210106 Japan;
Fospropofol (Lusedra®) 10
Grace Shih, MD
2011 - NCT01378754 United States;
Fospropofol (Lusedra®) 12
Grace Shih, MD
2011 - NCT01378754 United States;
Fospropofol (Lusedra®) 6.5
Grace Shih, MD
2011 - NCT01378754 United States;
Fremanezumab
Teva Branded Pharmaceutical Products R&D, Inc.
2020 Phase 2 NCT04447729 -
Gefapixant
Afferent Pharmaceuticals, Inc.
2012 Phase 2 NCT01569438 United States;
Glycine
Kimio Sugaya (Kitakami Central Hospital, and Southern Knights' Laboratory LLP)
2013 - JPRN-JMA-IIA00113 Japan;
Gralise
Shirley Ryan AbilityLab
2012 Phase 4 NCT01678911 United States;
Heparin
Department of Urology and Renal transplantation, Nagasaki University Hospital
2016 - JPRN-UMIN000027918 Japan;
Department of Urology, Mitsui Memorial Hospital
2016 Phase 2,3 JPRN-UMIN000026714 Japan;
University of Tokushima
2011 Phase 2 JPRN-UMIN000006387 Japan;
Urigen
2015 Phase 2 NCT02591199 United States;
Heparin & Alkalinized Lidocaine Bladder Instillation
Walter Reed National Military Medical Center
2020 Phase 2 NCT04401176 United States;
High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device
HillMed Inc.
2023 Early Phase 1 NCT05062902 United States;
Hyaluronic Acid and Chondroitin Sulfate
Samsung Medical Center
2017 - NCT03463499 Korea, Republic of;
Hyaluronic acid/chondroitin sulfate
Asan Medical Center
2013 - NCT01813565 Korea, Republic of;
Hydrogen
Koushinkai Hospital
2008 Phase 2,3 JPRN-UMIN000001253 Japan;
IC Cocktail
Capital District Health Authority, Canada
2006 Phase 2 NCT00317070 Canada;
IPD® (Japanese tradename)
Astellas Pharma Europe B.V.
2006 Phase 2 EUCTR2005-003367-23-DK Denmark;Germany;Sweden;
2006 - EUCTR2005-003367-23-SE Germany;Sweden;
2006 - EUCTR2005-003367-23-DE Germany;Sweden;
IPD® (suplatast tosilate)
Astellas Pharma Europe B.V.
2006 Phase 2 EUCTR2005-003367-23-DK Denmark;Germany;Sweden;
2006 - EUCTR2005-003367-23-SE Germany;Sweden;
Injections on posterior bladder wall excluding the trigone
Wake Forest University Health Sciences
2014 Phase 4 NCT02297100 United States;
Injections upper aspect of trigone of urinary bladder
Wake Forest University Health Sciences
2014 Phase 4 NCT02297100 United States;
Interferential current
Cairo University
2019 - NCT03844581 Egypt;
Intermittent Exposure to Oxygen via Oro-Nasal Mask
University of South Florida
2016 - NCT03693001 -
Intravesical onabotulinumtoxinA injection
Buddhist Tzu Chi General Hospital
2015 Phase 2 NCT03076762 Taiwan;
JNJ-42160443
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2010 Phase 2 NCT01060254 Canada;United States;
KRP-116D
Kyorin Pharmaceutical Co.,LTD
2017 Phase 3 JPRN-JapicCTI-173566 Japan;
Ketorolac Tromethamine
Citrus Valley Medical Research, Inc.
2012 Phase 4 NCT02000401 United States;
LP-08
Lipella Pharmaceuticals, Inc.
2015 Phase 2 NCT01393223 United States;
LiRIS
Allergan
2013 Phase 2 NCT01824303 Canada;United States;
LiRIS low dose and LiRIS high dose
Allergan
2010 Phase 1 NCT01150565 Canada;
LiRIS®
Allergan
2015 Phase 2 NCT02395042 Canada;United States;
2013 Phase 1 NCT01879683 United States;
Lidocaine
Department of Urology and Renal transplantation, Nagasaki University Hospital
2016 - JPRN-UMIN000027918 Japan;
Department of Urology, Mitsui Memorial Hospital
2016 Phase 2,3 JPRN-UMIN000026714 Japan;
Johns Hopkins University
2015 - NCT02517996 United States;
North Shore Long Island Jewish Health System
2009 - NCT00823030 United States;
Urigen
2015 Phase 2 NCT02591199 United States;
Lidocaine Releasing Intravesical System - LiRIS®
Allergan
2011 Phase 2 NCT01475253 Canada;United States;
Liposome encapsulated BoNT-A
Buddhist Tzu Chi General Hospital
2014 Phase 2 NCT02247557 Taiwan;
Liposomes
Kenneth Peters, MD
2012 - NCT01731470 United States;
2010 - NCT01083979 United States;
Low-dose naltrexone
NorthShore University HealthSystem
2021 Phase 4 NCT04313972 United States;
MN-001 BID
MediciNova
2005 Phase 2 NCT00295854 United States;
MR-MC-01
Asan Medical Center
2020 Phase 1 NCT04610359 Korea, Republic of;
Metoprolol Tartrate Oral Tablet
Medical College of Wisconsin
2017 Phase 4 NCT03008382 United States;
Mirabegron
Department of Urology, Graduate school of medicine, University of Tokyo
2012 - JPRN-UMIN000008484 Japan;
Philadelphia Urosurgical Associates
2016 Phase 3 NCT02787083 United States;
Mycofenolate Mofetil (MMF)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2007 Phase 3 NCT00451867 Canada;United States;
NALOXONE HYDROCHLORIDE
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
Naltrexone
Stanford University
2020 Phase 2 NCT04450316 United States;
Normal Saline
University of Rochester
2010 Phase 4 NCT01195116 United States;
Normal saline
Lipella Pharmaceuticals, Inc.
2015 Phase 2 NCT01393223 United States;
Normal saline instillation
Buddhist Tzu Chi General Hospital
2012 Phase 2 NCT01969773 Taiwan;
Nortriptyline
Duke University
2019 Phase 2 NCT03844412 United States;
OXN 10/5 mg PR
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
OXN 20/10 mg PR
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
OXN 5/2.5 mg PR
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
OXYCODONE HYDROCHLORIDE
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
Omalizumab
IRCCS Policlinico S. Matteo
2009 Phase 3 NCT01294878 Italy;
Onabotulinum Toxin A
Walter Reed National Military Medical Center
2020 Phase 2 NCT04401176 United States;
Onabotulinumtoxin A
Wake Forest University Health Sciences
2014 Phase 4 NCT02297100 United States;
Oxycodone naloxone prolonged release tablets
Mundipharma Research GmbH & Co KG
2010 Phase 2 NCT01197261 Czech Republic;Czechia;Germany;Hungary;Poland;United Kingdom;
Oxycodone/naloxone prolonged release t
Mundipharma Research GmbH & Co. KG
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
Oxycodone/naloxone prolonged release tablets 10/
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
Oxycodone/naloxone prolonged release tablets 20/
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
Oxycodone/naloxone prolonged release tablets 5/
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
Oxygen
Assaf-Harofeh Medical Center
2010 - NCT01069263 Israel;
Oxytocin
University of Alabama at Birmingham
2010 Phase 4 NCT00919802 United States;
Ozone
Anhembi Morumbi University
2020 Phase 2 NCT04789135 Brazil;
PD 0299685
Pfizer Ltd., Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
2008 - EUCTR2008-002421-37-FI Denmark;Finland;France;Germany;
2008 - EUCTR2008-002421-37-DK Denmark;Finland;France;Germany;
- - EUCTR2008-002421-37-DE Denmark;Finland;France;Germany;
PD 0299685 at 15mg BID
Pfizer
2008 Phase 2 NCT00739739 Canada;Denmark;Finland;France;Germany;United States;
PD 0299685 at 30mg BID
Pfizer
2008 Phase 2 NCT00739739 Canada;Denmark;Finland;France;Germany;United States;
PD-0299685
Pfizer Ltd
Ramsgate Road,Sandwich,Kent CT13 9NJ
PF-04383119
Pfizer
2008 Phase 2 NCT00601484 United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2010 Phase 2 EUCTR2009-014597-17-SK Belgium;Finland;Germany;Slovakia;Spain;Sweden;
2010 - EUCTR2009-014597-17-SE Belgium;Finland;Germany;Spain;Sweden;
2010 - EUCTR2009-014597-17-FI Belgium;Finland;Germany;Spain;Sweden;
2010 - EUCTR2009-014597-17-DE Belgium;Finland;Germany;Spain;Sweden;
2009 - EUCTR2009-014597-17-BE Belgium;Finland;Germany;Spain;Sweden;
Pfizer, S.A.
2010 - EUCTR2009-014597-17-ES Belgium;Finland;Germany;Spain;Sweden;
Pelvic Floor Physical Therapy
William Beaumont Hospitals
2017 Phase 2 NCT02870738 United States;
Pentosan polysulfate sodium
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2003 Phase 4 NCT00086684 Canada;United States;
Peppermint oil
University of Louisville
2021 Phase 1/Phase 2 NCT04845217 United States;
Placebo
Kyorin Pharmaceutical Co.,LTD
2017 Phase 3 JPRN-JapicCTI-173566 Japan;
Platelet enriched plasma
Mansoura University
2019 Phase 1/Phase 2 NCT04118946 Egypt;
Platelet-Rich Plasma
Buddhist Tzu Chi General Hospital
2017 Phase 1 NCT03104361 Taiwan;
Prograf
Jukka Sairanen
2008 - EUCTR2008-001501-42-FI Finland;
Propiverine Hydrochloride
Cairo University
2019 - NCT03844581 Egypt;
RN624, RI624
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2010 Phase 2 EUCTR2009-014597-17-SK Belgium;Finland;Germany;Slovakia;Spain;Sweden;
2010 - EUCTR2009-014597-17-SE Belgium;Finland;Germany;Spain;Sweden;
2010 - EUCTR2009-014597-17-FI Belgium;Finland;Germany;Spain;Sweden;
2010 - EUCTR2009-014597-17-DE Belgium;Finland;Germany;Spain;Sweden;
2009 - EUCTR2009-014597-17-BE Belgium;Finland;Germany;Spain;Sweden;
Pfizer, S.A.
2010 - EUCTR2009-014597-17-ES Belgium;Finland;Germany;Spain;Sweden;
SANDIMMUN
Oulu University Hospital
2015 - EUCTR2015-004495-30-FI Finland;
SI-722
Seikagaku Corporation
2020 Phase 1/Phase 2 NCT04208087 United States;
Sandimmun Neoral
Ingrid Ehrén
2005 - EUCTR2005-000890-23-SE Sweden;
Sham Cystoscopy Procedure
Allergan
2011 Phase 2 NCT01475253 Canada;United States;
Sildenafil
The First Af?liated Hospital of Wenzhou Medical College
2009 - ChiCTR-TRC-13003938 China;
Suplatast tosilate
Astellas Pharma Europe B.V.
2006 - EUCTR2005-003367-23-DE Germany;Sweden;
TTI-1612
Trillium Therapeutics Inc.
2012 Phase 1 NCT01559961 Canada;
Tanezumab
Pfizer
2010 Phase 2 NCT00999518 Belgium;Canada;Finland;Germany;Hong Kong;India;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;United States;
2009 Phase 1 NCT01030640 United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2010 Phase 2 EUCTR2009-014597-17-SK Belgium;Finland;Germany;Slovakia;Spain;Sweden;
2010 - EUCTR2009-014597-17-SE Belgium;Finland;Germany;Spain;Sweden;
2010 - EUCTR2009-014597-17-FI Belgium;Finland;Germany;Spain;Sweden;
2010 - EUCTR2009-014597-17-DE Belgium;Finland;Germany;Spain;Sweden;
2009 - EUCTR2009-014597-17-BE Belgium;Finland;Germany;Spain;Sweden;
Pfizer, S.A.
2010 - EUCTR2009-014597-17-ES Belgium;Finland;Germany;Spain;Sweden;
Targinact 10 mg/5 mg prolonged-release tablets
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
Targinact 20mg/10 mg prolonged-release tablets
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
Targinact 5mg/2.5 mg prolonged-release tablets
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
Tissue examination for protein- and mRNA-expression of NO
Copenhagen University Hospital at Herlev
2006 - NCT00253006 Denmark;
Tramadol
Departmen of Urology, The University of Tokyo Hospital
2014 - JPRN-UMIN000009197 Japan;
URG101
Urigen
2015 Phase 2 NCT02591199 United States;
2007 Phase 2 NCT00517868 United States;
Urodynamic study
North Shore Long Island Jewish Health System
2009 - NCT00823030 United States;
Water
Koushinkai Hospital
2008 Phase 2,3 JPRN-UMIN000001253 Japan;
YM672 (IPD®)
Astellas Pharma Europe B.V.
2006 Phase 2 EUCTR2005-003367-23-DK Denmark;Germany;Sweden;
2006 - EUCTR2005-003367-23-SE Germany;Sweden;
2006 - EUCTR2005-003367-23-DE Germany;Sweden;
lidocaine/5 mg/ml estradiol compound cream
Duke University
2019 Phase 2 NCT03844412 United States;
sodium chondroitin sulfate
Watson Pharmaceuticals
2009 Phase 2 NCT00919113 United States;
Allergan
2006 Phase 2 NCT00380783 United States;
AQX-1125
Aquinox Pharmaceuticals (Canada) Inc.
2017 Phase 3 EUCTR2016-000906-12-NL Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000906-12-ES Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000906-12-BE Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States;
2016 Phase 3 NCT02858453 Belgium;Canada;Czech Republic;Czechia;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000906-12-LV Belgium;Canada;Czech Republic;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000906-12-HU Belgium;Canada;Czech Republic;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000906-12-GB Belgium;Canada;Czech Republic;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000906-12-DK Belgium;Canada;Czech Republic;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000906-12-CZ Belgium;Canada;Czech Republic;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;United States;
2013 Phase 2 NCT01882543 Canada;United States;
ASP3652
Astellas Pharma Europe B.V.
2013 - EUCTR2011-004555-39-LT Belgium;Czech Republic;Denmark;France;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 Phase 2 NCT01613586 Belgium;Czech Republic;Czechia;Denmark;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 Phase 2 EUCTR2011-004555-39-BE Belgium;Czech Republic;Denmark;France;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 - EUCTR2011-004555-39-PT Belgium;Czech Republic;Denmark;France;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 - EUCTR2011-004555-39-PL Belgium;Czech Republic;Denmark;France;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 - EUCTR2011-004555-39-NL Belgium;Czech Republic;Denmark;France;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 - EUCTR2011-004555-39-LV Belgium;Czech Republic;Denmark;France;Germany;Italy;Latvia;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 - EUCTR2011-004555-39-ES Belgium;Czech Republic;Denmark;France;Germany;Latvia;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 - EUCTR2011-004555-39-DK Belgium;Czech Republic;Denmark;France;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 - EUCTR2011-004555-39-DE Belgium;Czech Republic;Denmark;France;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
2012 - EUCTR2011-004555-39-CZ Belgium;Czech Republic;Denmark;France;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;
ASP6294
Astellas Pharma Europe B.V.
2017 Phase 2 NCT03282318 Belgium;Czechia;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004138-12-PL Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004138-12-NL Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004138-12-LV Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004138-12-HU Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004138-12-GB Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004138-12-ES Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004138-12-DE Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004138-12-CZ Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004138-12-BE Belgium;Czech Republic;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
Adalimumab
ICStudy, LLC
2011 Phase 3 NCT01295814 United States;
Alkalinized Lidocaine-Heparin
Urigen
2006 Phase 2 NCT00256542 United States;
AlloRx
The Foundation for Orthopaedics and Regenerative Medicine
2021 Phase 1 NCT05147779 Antigua and Barbuda;
Amitriptyline
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2005 Phase 3 NCT00124306 Canada;United States;
BOTOX 100U in normal saline
Buddhist Tzu Chi General Hospital
2021 Phase 2 NCT05275647 Taiwan;
BOTOX 200U in normal saline
Buddhist Tzu Chi General Hospital
2014 Phase 2 NCT02247557 Taiwan;
Bladder Instillations
William Beaumont Hospitals
2017 Phase 2 NCT02870738 United States;
Bladder instillation WITH triamcinolone acetonide
Olivia Cardenas-Trowers, M.D.
2019 Phase 3 NCT03463915 United States;
Bladder instillation WITHOUT triamcinolone acetonide
Olivia Cardenas-Trowers, M.D.
2019 Phase 3 NCT03463915 United States;
Bladder instillation with heparin/ lidocaine
Scripps Health
2012 Phase 2 NCT01048177 United States;
Botox
University of Washington
2004 Phase 4 NCT00194610 United States;
research office urology VUmc
2008 - EUCTR2007-005164-27-NL Netherlands;
Botulinum toxin A
Buddhist Tzu Chi General Hospital
2012 Phase 2 NCT01969773 Taiwan;
Buckwheat
Center for Pharma-Food Research, Graduate School of Pharmaceutical Sciences, University of Shizuoka
2017 - JPRN-UMIN000029113 Japan;
Bupivacaine
Case Western Reserve University
2009 - NCT01616992 United States;
Bupivacaine, triamcinolone, and heparin (BTH)
NorthShore University HealthSystem
2011 Phase 4 NCT05223244 -
Cannabidiol vaginal suppository
University of New Mexico
2021 Phase 1 NCT04349930 United States;
Capsaicin
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1995 Phase 1/Phase 2 NCT00004316 -
Certolizumab pegol
ICStudy, LLC
2015 Phase 3 NCT02497976 United States;
Ciklosporin
Ingrid Ehrén
2005 - EUCTR2005-000890-23-SE Sweden;
Combination Product: Hyperbaric Oxygen Therapy-
University of California, San Diego
2017 Early Phase 1 NCT03143920 United States;
Cyclosporine
The Cleveland Clinic
2013 Phase 2 NCT01990898 United States;
DMSO
Assaf-Harofeh Medical Center
2010 - NCT01069263 Israel;
Deparment of Urology, Medical Science, University of Fukui
2005 - JPRN-UMIN000003172 Japan;
Department of Urology, Hamamatsu University School of Medicine
2004 - JPRN-UMIN000027494 Japan;
Urology, Hokkaido University Graduate School of Medicine
2014 - JPRN-UMIN000014860 Japan;
DMSO cocktail
Assaf-Harofeh Medical Center
2009 - NCT01074567 Israel;
Desert Harvest Aloe Vera Capsules
Wake Forest University Health Sciences
2022 Early Phase 1 NCT04734106 United States;
Dexmedetomidine
University of Rochester
2010 Phase 4 NCT01195116 United States;
Dextrose
National Defense Medical Center, Taiwan
2019 - NCT04821882 Taiwan;
Dimethyl sulfoxide
Capital District Health Authority, Canada
2006 Phase 2 NCT00317070 Canada;
IBSA
2011 - EUCTR2010-021556-25-IT Italy;
Kyorin Pharmaceutical Co.,LTD
2017 Phase 3 JPRN-JapicCTI-173566 Japan;
Dimethyl sulfoxide (DMSO)
NorthShore University HealthSystem
2011 Phase 4 NCT05223244 -
ERB-041
Wyeth is now a wholly owned subsidiary of Pfizer
2006 - NCT00275379 Austria;Germany;United States;
Flavoxate
Torimoto Kazumasa
2021 Phase 2 JPRN-jRCTs051210106 Japan;
Fospropofol (Lusedra®) 10
Grace Shih, MD
2011 - NCT01378754 United States;
Fospropofol (Lusedra®) 12
Grace Shih, MD
2011 - NCT01378754 United States;
Fospropofol (Lusedra®) 6.5
Grace Shih, MD
2011 - NCT01378754 United States;
Fremanezumab
Teva Branded Pharmaceutical Products R&D, Inc.
2020 Phase 2 NCT04447729 -
Gefapixant
Afferent Pharmaceuticals, Inc.
2012 Phase 2 NCT01569438 United States;
Glycine
Kimio Sugaya (Kitakami Central Hospital, and Southern Knights' Laboratory LLP)
2013 - JPRN-JMA-IIA00113 Japan;
Gralise
Shirley Ryan AbilityLab
2012 Phase 4 NCT01678911 United States;
Heparin
Department of Urology and Renal transplantation, Nagasaki University Hospital
2016 - JPRN-UMIN000027918 Japan;
Department of Urology, Mitsui Memorial Hospital
2016 Phase 2,3 JPRN-UMIN000026714 Japan;
University of Tokushima
2011 Phase 2 JPRN-UMIN000006387 Japan;
Urigen
2015 Phase 2 NCT02591199 United States;
Heparin & Alkalinized Lidocaine Bladder Instillation
Walter Reed National Military Medical Center
2020 Phase 2 NCT04401176 United States;
High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device
HillMed Inc.
2023 Early Phase 1 NCT05062902 United States;
Hyaluronic Acid and Chondroitin Sulfate
Samsung Medical Center
2017 - NCT03463499 Korea, Republic of;
Hyaluronic acid/chondroitin sulfate
Asan Medical Center
2013 - NCT01813565 Korea, Republic of;
Hydrogen
Koushinkai Hospital
2008 Phase 2,3 JPRN-UMIN000001253 Japan;
IC Cocktail
Capital District Health Authority, Canada
2006 Phase 2 NCT00317070 Canada;
IPD® (Japanese tradename)
Astellas Pharma Europe B.V.
2006 Phase 2 EUCTR2005-003367-23-DK Denmark;Germany;Sweden;
2006 - EUCTR2005-003367-23-SE Germany;Sweden;
2006 - EUCTR2005-003367-23-DE Germany;Sweden;
IPD® (suplatast tosilate)
Astellas Pharma Europe B.V.
2006 Phase 2 EUCTR2005-003367-23-DK Denmark;Germany;Sweden;
2006 - EUCTR2005-003367-23-SE Germany;Sweden;
Injections on posterior bladder wall excluding the trigone
Wake Forest University Health Sciences
2014 Phase 4 NCT02297100 United States;
Injections upper aspect of trigone of urinary bladder
Wake Forest University Health Sciences
2014 Phase 4 NCT02297100 United States;
Interferential current
Cairo University
2019 - NCT03844581 Egypt;
Intermittent Exposure to Oxygen via Oro-Nasal Mask
University of South Florida
2016 - NCT03693001 -
Intravesical onabotulinumtoxinA injection
Buddhist Tzu Chi General Hospital
2015 Phase 2 NCT03076762 Taiwan;
JNJ-42160443
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2010 Phase 2 NCT01060254 Canada;United States;
KRP-116D
Kyorin Pharmaceutical Co.,LTD
2017 Phase 3 JPRN-JapicCTI-173566 Japan;
Ketorolac Tromethamine
Citrus Valley Medical Research, Inc.
2012 Phase 4 NCT02000401 United States;
LP-08
Lipella Pharmaceuticals, Inc.
2015 Phase 2 NCT01393223 United States;
LiRIS
Allergan
2013 Phase 2 NCT01824303 Canada;United States;
LiRIS low dose and LiRIS high dose
Allergan
2010 Phase 1 NCT01150565 Canada;
LiRIS®
Allergan
2015 Phase 2 NCT02395042 Canada;United States;
2013 Phase 1 NCT01879683 United States;
Lidocaine
Department of Urology and Renal transplantation, Nagasaki University Hospital
2016 - JPRN-UMIN000027918 Japan;
Department of Urology, Mitsui Memorial Hospital
2016 Phase 2,3 JPRN-UMIN000026714 Japan;
Johns Hopkins University
2015 - NCT02517996 United States;
North Shore Long Island Jewish Health System
2009 - NCT00823030 United States;
Urigen
2015 Phase 2 NCT02591199 United States;
Lidocaine Releasing Intravesical System - LiRIS®
Allergan
2011 Phase 2 NCT01475253 Canada;United States;
Liposome encapsulated BoNT-A
Buddhist Tzu Chi General Hospital
2014 Phase 2 NCT02247557 Taiwan;
Liposomes
Kenneth Peters, MD
2012 - NCT01731470 United States;
2010 - NCT01083979 United States;
Low-dose naltrexone
NorthShore University HealthSystem
2021 Phase 4 NCT04313972 United States;
MN-001 BID
MediciNova
2005 Phase 2 NCT00295854 United States;
MR-MC-01
Asan Medical Center
2020 Phase 1 NCT04610359 Korea, Republic of;
Metoprolol Tartrate Oral Tablet
Medical College of Wisconsin
2017 Phase 4 NCT03008382 United States;
Mirabegron
Department of Urology, Graduate school of medicine, University of Tokyo
2012 - JPRN-UMIN000008484 Japan;
Philadelphia Urosurgical Associates
2016 Phase 3 NCT02787083 United States;
Mycofenolate Mofetil (MMF)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2007 Phase 3 NCT00451867 Canada;United States;
NALOXONE HYDROCHLORIDE
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
Naltrexone
Stanford University
2020 Phase 2 NCT04450316 United States;
Normal Saline
University of Rochester
2010 Phase 4 NCT01195116 United States;
Normal saline
Lipella Pharmaceuticals, Inc.
2015 Phase 2 NCT01393223 United States;
Normal saline instillation
Buddhist Tzu Chi General Hospital
2012 Phase 2 NCT01969773 Taiwan;
Nortriptyline
Duke University
2019 Phase 2 NCT03844412 United States;
OXN 10/5 mg PR
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
OXN 20/10 mg PR
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
OXN 5/2.5 mg PR
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
OXYCODONE HYDROCHLORIDE
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
Omalizumab
IRCCS Policlinico S. Matteo
2009 Phase 3 NCT01294878 Italy;
Onabotulinum Toxin A
Walter Reed National Military Medical Center
2020 Phase 2 NCT04401176 United States;
Onabotulinumtoxin A
Wake Forest University Health Sciences
2014 Phase 4 NCT02297100 United States;
Oxycodone naloxone prolonged release tablets
Mundipharma Research GmbH & Co KG
2010 Phase 2 NCT01197261 Czech Republic;Czechia;Germany;Hungary;Poland;United Kingdom;
Oxycodone/naloxone prolonged release t
Mundipharma Research GmbH & Co. KG
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
Oxycodone/naloxone prolonged release tablets 10/
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
Oxycodone/naloxone prolonged release tablets 20/
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
Oxycodone/naloxone prolonged release tablets 5/
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
Oxygen
Assaf-Harofeh Medical Center
2010 - NCT01069263 Israel;
Oxytocin
University of Alabama at Birmingham
2010 Phase 4 NCT00919802 United States;
Ozone
Anhembi Morumbi University
2020 Phase 2 NCT04789135 Brazil;
PD 0299685
Pfizer Ltd., Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
2008 - EUCTR2008-002421-37-FI Denmark;Finland;France;Germany;
2008 - EUCTR2008-002421-37-DK Denmark;Finland;France;Germany;
- - EUCTR2008-002421-37-DE Denmark;Finland;France;Germany;
PD 0299685 at 15mg BID
Pfizer
2008 Phase 2 NCT00739739 Canada;Denmark;Finland;France;Germany;United States;
PD 0299685 at 30mg BID
Pfizer
2008 Phase 2 NCT00739739 Canada;Denmark;Finland;France;Germany;United States;
PD-0299685
Pfizer Ltd
Ramsgate Road,Sandwich,Kent CT13 9NJ
PF-04383119
Pfizer
2008 Phase 2 NCT00601484 United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2010 Phase 2 EUCTR2009-014597-17-SK Belgium;Finland;Germany;Slovakia;Spain;Sweden;
2010 - EUCTR2009-014597-17-SE Belgium;Finland;Germany;Spain;Sweden;
2010 - EUCTR2009-014597-17-FI Belgium;Finland;Germany;Spain;Sweden;
2010 - EUCTR2009-014597-17-DE Belgium;Finland;Germany;Spain;Sweden;
2009 - EUCTR2009-014597-17-BE Belgium;Finland;Germany;Spain;Sweden;
Pfizer, S.A.
2010 - EUCTR2009-014597-17-ES Belgium;Finland;Germany;Spain;Sweden;
Pelvic Floor Physical Therapy
William Beaumont Hospitals
2017 Phase 2 NCT02870738 United States;
Pentosan polysulfate sodium
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2003 Phase 4 NCT00086684 Canada;United States;
Peppermint oil
University of Louisville
2021 Phase 1/Phase 2 NCT04845217 United States;
Placebo
Kyorin Pharmaceutical Co.,LTD
2017 Phase 3 JPRN-JapicCTI-173566 Japan;
Platelet enriched plasma
Mansoura University
2019 Phase 1/Phase 2 NCT04118946 Egypt;
Platelet-Rich Plasma
Buddhist Tzu Chi General Hospital
2017 Phase 1 NCT03104361 Taiwan;
Prograf
Jukka Sairanen
2008 - EUCTR2008-001501-42-FI Finland;
Propiverine Hydrochloride
Cairo University
2019 - NCT03844581 Egypt;
RN624, RI624
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2010 Phase 2 EUCTR2009-014597-17-SK Belgium;Finland;Germany;Slovakia;Spain;Sweden;
2010 - EUCTR2009-014597-17-SE Belgium;Finland;Germany;Spain;Sweden;
2010 - EUCTR2009-014597-17-FI Belgium;Finland;Germany;Spain;Sweden;
2010 - EUCTR2009-014597-17-DE Belgium;Finland;Germany;Spain;Sweden;
2009 - EUCTR2009-014597-17-BE Belgium;Finland;Germany;Spain;Sweden;
Pfizer, S.A.
2010 - EUCTR2009-014597-17-ES Belgium;Finland;Germany;Spain;Sweden;
SANDIMMUN
Oulu University Hospital
2015 - EUCTR2015-004495-30-FI Finland;
SI-722
Seikagaku Corporation
2020 Phase 1/Phase 2 NCT04208087 United States;
Sandimmun Neoral
Ingrid Ehrén
2005 - EUCTR2005-000890-23-SE Sweden;
Sham Cystoscopy Procedure
Allergan
2011 Phase 2 NCT01475253 Canada;United States;
Sildenafil
The First Af?liated Hospital of Wenzhou Medical College
2009 - ChiCTR-TRC-13003938 China;
Suplatast tosilate
Astellas Pharma Europe B.V.
2006 - EUCTR2005-003367-23-DE Germany;Sweden;
TTI-1612
Trillium Therapeutics Inc.
2012 Phase 1 NCT01559961 Canada;
Tanezumab
Pfizer
2010 Phase 2 NCT00999518 Belgium;Canada;Finland;Germany;Hong Kong;India;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;United States;
2009 Phase 1 NCT01030640 United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2010 Phase 2 EUCTR2009-014597-17-SK Belgium;Finland;Germany;Slovakia;Spain;Sweden;
2010 - EUCTR2009-014597-17-SE Belgium;Finland;Germany;Spain;Sweden;
2010 - EUCTR2009-014597-17-FI Belgium;Finland;Germany;Spain;Sweden;
2010 - EUCTR2009-014597-17-DE Belgium;Finland;Germany;Spain;Sweden;
2009 - EUCTR2009-014597-17-BE Belgium;Finland;Germany;Spain;Sweden;
Pfizer, S.A.
2010 - EUCTR2009-014597-17-ES Belgium;Finland;Germany;Spain;Sweden;
Targinact 10 mg/5 mg prolonged-release tablets
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
Targinact 20mg/10 mg prolonged-release tablets
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
Targinact 5mg/2.5 mg prolonged-release tablets
Mundipharma Research GmbH & Co. KG
2010 Phase 2 EUCTR2009-018118-21-GB Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-HU Czech Republic;Germany;Hungary;United Kingdom;
2010 - EUCTR2009-018118-21-CZ Czech Republic;Germany;Hungary;United Kingdom;
- - EUCTR2009-018118-21-DE Czech Republic;Germany;Hungary;United Kingdom;
Tissue examination for protein- and mRNA-expression of NO
Copenhagen University Hospital at Herlev
2006 - NCT00253006 Denmark;
Tramadol
Departmen of Urology, The University of Tokyo Hospital
2014 - JPRN-UMIN000009197 Japan;
URG101
Urigen
2015 Phase 2 NCT02591199 United States;
2007 Phase 2 NCT00517868 United States;
Urodynamic study
North Shore Long Island Jewish Health System
2009 - NCT00823030 United States;
Water
Koushinkai Hospital
2008 Phase 2,3 JPRN-UMIN000001253 Japan;
YM672 (IPD®)
Astellas Pharma Europe B.V.
2006 Phase 2 EUCTR2005-003367-23-DK Denmark;Germany;Sweden;
2006 - EUCTR2005-003367-23-SE Germany;Sweden;
2006 - EUCTR2005-003367-23-DE Germany;Sweden;
lidocaine/5 mg/ml estradiol compound cream
Duke University
2019 Phase 2 NCT03844412 United States;
sodium chondroitin sulfate
Watson Pharmaceuticals
2009 Phase 2 NCT00919113 United States;